Aktuelle Standards in der Diagnostik und chirurgischen Therapie pankreatischer neuroendokriner Tumoren

Ioannis Mintziras; Katharina Holzer

doi:10.1055/a-2327-4179

Allgemein- und Viszeralchirurgie up2date, Table of Contents

Allgemein- und Viszeralchirurgie up2date 2025; 19(01): 13-28
DOI: 10.1055/a-2327-4179

Endokrine Chirurgie

Aktuelle Standards in der Diagnostik und chirurgischen Therapie pankreatischer neuroendokriner Tumoren

Ioannis Mintziras

¹Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen und Marburg - Standort Marburg, Marburg, Germany (Ringgold ID: RIN61061)

,

Katharina Holzer

¹Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen und Marburg - Standort Marburg, Marburg, Germany (Ringgold ID: RIN61061)

› Author Affiliations

Abstract

All articles of this category

Pankreatische neuroendokrine Tumoren (Pan-NET) sind seltene, heterogene Tumoren mit komplexer Diagnostik und Therapie. Das variable Verhalten dieser Tumoren schließt eine einheitliche chirurgische Strategie aus. Dieser Beitrag beleuchtet aktuelle Standards in der Diagnostik und chirurgischen Behandlung, diskutiert innovative Ansätze wie ultraschallgestützte Verfahren und gibt Einblicke in die Bedeutung systemischer Therapien.

Schlüsselwörter

Pan-NEN - Pan-NET - neuroendokriner Tumor - Pankreas - chirurgische Therapie

Full Text

References

Literatur
1 Hallet J, Law CHL, Cukier M. et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121: 589-597
2 Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: Clinical features, diagnosis and medical treatment: Advances. Best Pract Res Clin Gastroenterol 2012; 26: 737-753
3 Nagtegaal ID, Odze RD, Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182-188
4 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072
5 Coriat R, Walter T, Terris B. et al. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 2016; 21: 1191-1199
6 Yachida S, Vakiani E, White CM. et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012; 36: 173-184
7 Jiao Y, Shi C, Edil BH. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203
8 Basturk O, Yang Z, Tang LH. et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39: 683-690
9 Morizane C, Machida N, Honma Y. et al. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients with Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol 2022; 8: 1447-1455
10 Burns WR, Edil BH. Neuroendocrine pancreatic tumors: Guidelines for management and update. Curr Treat Options Oncol 2012; 13: 24-34
11 Niederle B, Selberherr A, Bartsch DK. et al. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome – An International Consensus Statement. Neuroendocrinology 2021; 111: 609-630
12 Pieterman CRC, Valk GD. Update on the clinical management of multiple endocrine neoplasia type 1. Clin Endocrinol 2022; 97: 409-423
13 Soczomski P, Jurecka-Lubieniecka B, Krzywon A. et al. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021; 12: 681013
14 Hofland J, Falconi M, Christ E. et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 2023; 35: e13318
15 Halfdanarson TR, Rabe KG, Rubin J. et al. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19: 1727-1733
16 Perri G, Prakash LR, Katz MHG. Pancreatic neuroendocrine tumors. Curr Opin Gastroenterol 2019; 35: 468-477
17 Keutgen XM, Nilubol N, Kebebew E. Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis. Surgery 2016; 159: 1382-1389
18 Ito T, Igarashi H, Nakamura K. et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 2015; 50: 58-64
19 Peltola E, Hannula P, Huhtala H. et al. Long-term morbidity and mortality in patients diagnosed with an insulinoma. Eur J Endocrinol 2021; 185: 577-586
20 Service FJ, McMahon MM, O’Brien PC. et al. Functioning Insulinoma – Incidence, Recurrence, and Long-Term Survival of Patients: A 60-Year Study. Mayo Clin Proc 1991; 66: 711-719
21 Elkelany OO, Karaisz FG, Davies B. et al. An Overview of Pancreatic Neuroendocrine Tumors and an Update on Endoscopic Techniques for Their Management. Curr Oncol 2023; 30: 7566-7580
22 Okabayashi T, Shima Y, Sumiyoshi T. et al. Diagnosis and management of insulinoma. World J Gastroenterol 2013; 19: 829-837
23 Bevere M, Gkountakos A, Martelli FM. et al. An Insight on Functioning Pancreatic Neuroendocrine Neoplasms. Biomedicines 2023; 11: 303
24 Kauhanen S, Seppänen M, Minn H. et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or β-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007; 92: 1237-1244
25 Rossi RE, Elvevi A, Citterio D. et al. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World J Gastroenterol 2021; 27: 5890-5907
26 Magi L, Marasco M, Rinzivillo M. et al. Management of Functional Pancreatic Neuroendocrine Neoplasms. Curr Treat Options Oncol 2023; 24: 725-741
27 Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult. World J Gastroenterol 2012; 18: 5495-5503
28 Metz DC, Cadiot G, Poitras P. et al. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol 2017; 4: 167-185
29 Khashab MA, Yong E, Lennon AM. et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73: 691-696
30 Rindi G, Mete O, Uccella S. et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 2022; 33: 115-154
31 Mastoraki A, Schizas D, Papoutsi E. et al. Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas. In Vivo 2020; 34: 3573-3582
32 Garbrecht N, Anlauf M, Schmitt A. et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: Incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008; 15: 229-241
33 Krausz Y, Freedman N, Rubinstein R. et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: Comparison with 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011; 13: 583-593
34 Anderson CW, Bennett JJ. Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2016; 25: 363-374
35 Siddappa PK, Vege SS. Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas 2019; 48: 1119-1125
36 Alshareefy Y, Cummins S, Sharma V. et al. A review of functional pancreatic neuroendocrine tumors Exploring the molecular pathogenesis, diagnosis and treatment. Medicine (Baltimore) 2023; 102: e36094
37 Crona J, Skogseid B. Genetics of neuroendocrine tumors. Eur J Endocrinol 2016; 174: R275-R290
38 Pipinikas CP, Berner AM, Sposito T. et al. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours. Endocr Relat Cancer 2019; 26: R519-R544
39 Capurso G, Festa S, Valente R. et al. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol 2012; 49: R37-R50
40 Pea A, Hruban RH, Wood LD. Genetics of pancreatic neuroendocrine tumors: Implications for the clinic. Expert Rev Gastroenterol Hepatol 2015; 9: 1407-1419
41 Belfiori G, Wiese D, Partelli S. et al. Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. World J Surg 2018; 42: 3223-3230
42 Santucci N, Gaujoux S, Binquet C. et al. Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d’étude des Tumeurs Endocrines) Study. World J Surg 2021; 45: 1794-1802
43 Kong W, Albers MB, Manoharan J. et al. Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger–Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1. Cancers (Basel) 2022; 14: 1928
44 Anlauf M, Garbrecht N, Henopp T. et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: Distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 12: 5440-5446
45 Norton JA, Krampitz GW, Poultsides GA. et al. Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome. Ann Surg 2018; 267: 782-788
46 van Beek DJ, Nell S, Pieterman CRC. et al. Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG). J Surg Oncol 2019; 120: 966-975
47 Clancy TE. Surgical Management of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016; 30: 103-118
48 Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004; 120: 139-161
49 Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol 2015; 21: 9512-9525
50 Heidsma CM, Engelsman AF, Van Dieren S. et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: Nationwide prospective cohort study (PANDORA). Br J Surg 2021; 108: 888-891
51 Partelli S, Massironi S, Zerbi A. et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: Interim analysis of prospective ASPEN trial. Br J Surg 2022; 109: 1186-1190
52 Kos-Kudła B, Castaño JP, Denecke T. et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol 2023; 35: e13343
53 Tsoli M, Spei ME, Wallin G. et al. Association of a palliative surgical approach to stage IV pancreatic neuroendocrine neoplasms with survival: A systematic review and meta-analysis. Cancers (Basel) 2020; 12: 2246
54 Mou Y, Wang ZY, Tan CL. et al. The Role of Primary Tumor Resection in Patients With Pancreatic Neuroendocrine Tumors With Liver Metastases. Front Oncol 2022; 12: 838103
55 Tsilimigras DI, Hyer JM, Paredes AZ. et al. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis. J Gastrointest Surg 2021; 25: 2368-2376
56 Kjaer J, Clancy TE, Thornell A. et al. Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors. Ann Surg Open 2022; 3: e151
57 Sulciner ML, Clancy TE. Surgical Management of Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2023; 15: 2006
58 Dermine S, Palmieri LJ, Lavolé J. et al. Non-pharmacological therapeutic options for liver metastases in advanced neuroendocrine tumors. J Clin Med 2019; 8: 1907
59 So H, Ko SW, Shin SH. et al. Comparison of EUS-guided ablation and surgical resection for nonfunctioning small pancreatic neuroendocrine tumors: a propensity score-matching study. Gastrointest Endosc 2023; 97: 741-751.e1
60 Garg R, Mohammed A, Singh A. et al. EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine tumors: A systematic review and meta-analysis. Endosc Ultrasound 2022; 11: 170-185
61 Imperatore N, de Nucci G, Mandelli ED. et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature. Endosc Int Open 2020; 8: E1759-E1764
62 Raymond E, Dahan L, Raoul JL. et al. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med 2011; 364: 501-513
63 Smith D, Lepage C, Vicaut E. et al. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study. Adv Ther 2022; 39: 2731-2748
64 Strosberg JR, Caplin ME, Kunz PL. et al. 177Lu-Dotatate plus long-acting octreotide versus high?dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22: 1752-1763
65 Pavel M, Öberg K, Falconi M. et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 844-860
66 Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin 2018; 68: 471-487
67 Cloyd JM, Omichi K, Mizuno T. et al. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol 2018; 25: 1709-1715